Skip to main content
Premium Trial:

Request an Annual Quote

Tempus Raises $80M

NEW YORK (GenomeWeb) – Tempus announced yesterday that it has raised $80 million in a new round of financing.

The round included existing investors New Enterprise Associates and Revolution Growth, as well as new investor Kinship Trust Company, and follows a $70 million Series C round in September. To date, Tempus has raised $210 million.

Tempus provides genomic sequencing and data analysis services to help guide treatment decisions for cancer patients. The company said it will use the new funds grow and scale its clinical and molecular analytic platform.

In January, the firm announced it had partnered with the NYU School of Medicine to generate and analyze genomic data from pancreatic cancer patients to help develop personalized treatments for the disease. Tempus has also formed personalized cancer medicine alliances with a number of research organizations, including the Vanderbilt-Ingram Cancer Center, the Cleveland Clinic, and the University of California Davis Comprehensive Cancer Center.